General MedicationsSUBCUTANEOUSStandard
TEZSPIRE
TEZEPELUMAB-EKKO
Standard Dose
210MG/1.91ML(110MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview TEZSPIRE is listed in Drugs@FDA under application 761224 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient TEZEPELUMAB-EKKO Form and strength SOLUTION;SUBCUTANEOUS - 210MG/1.91ML(110MG/ML) Sponsor ASTRAZENECA AB Submission history Latest submission status date: 2025-10-17 00:00:00.
Structured Monograph
Clinical summary
Approval overview TEZSPIRE is listed in Drugs@FDA under application 761224 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient TEZEPELUMAB-EKKO Form and strength SOLUTION;SUBCUTANEOUS - 210MG/1.91ML(110MG/ML) Sponsor ASTRAZENECA AB Submission history Latest submission status date: 2025-10-17 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.